Scarica l'app Stockscreener
8.91
3.47%
-0.32
Dopo l'orario di chiusura:
8.86
-0.05
-0.56%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$9.23
Aprire:
$9.38
Volume 24 ore:
800.33K
Relative Volume:
1.69
Capitalizzazione di mercato:
$152.82M
Reddito:
$13.11M
Utile/perdita netta:
$-124.02M
Rapporto P/E:
-0.6248
EPS:
-14.261
Flusso di cassa netto:
$-107.25M
1 W Prestazione:
-9.63%
1M Prestazione:
-33.41%
6M Prestazione:
-35.90%
1 anno Prestazione:
-63.96%
Intervallo 1D:
$8.69
$9.56
Intervallo di 1 settimana:
$8.69
$10.08
Portata 52W:
$8.69
$25.40
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
8.91 | 169.11M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Why Is Tonix Pharmaceuticals (NASDAQ:TNXP) Moving Into Focus? - kalkinemedia.com
Tonix Pharmaceuticals Holding (TNXP) Stock Price, News & Analysis - Stock Titan
How (TNXP) Movements Inform Risk Allocation Models - Stock Traders Daily
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell - MarketBeat
Tonix Pharmaceuticals (TNXP) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Tonix expands Medicare coverage for fibromyalgia drug TONMYA By Investing.com - Investing.com Nigeria
Tonix expands Medicare coverage for fibromyalgia drug TONMYA - Investing.com
Tonix Pharmaceuticals Adds ~21M Medicare Lives for TONMYA, Total Coverage Now ~166M U.S. Lives - TradingView
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® - GlobeNewswire
Raymond James reiterates Strong Buy on Tonix Pharma stock at $27 - Investing.com Nigeria
Analysts Are Bullish on Top Healthcare Stocks: ALX Oncology Holdings (ALXO), Tonix Pharma (TNXP) - The Globe and Mail
Tonix Pharmaceuticals Holding Corp. (TNXP) Key Financial Ratios – Valuation, Profitability & More - Value Research
The Technical Signals Behind (TNXP) That Institutions Follow - Stock Traders Daily
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - marketbeat.com
Could Market Volatility Test Tonix Pharmaceuticals (NASDAQ:TNXP)? - Kalkine Media
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com Canada
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push - Investing.com
Q3 EPS Estimate for Tonix Pharmaceuticals Raised by Analyst - marketbeat.com
What macro factors could move Tonix Pharmaceuticals (NASDAQ:TNXP) shares this week? - Kalkine Media
Tonix Pharma Appoints New Chief Commercial Officer - The Globe and Mail
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving AverageWhat's Next? - marketbeat.com
symbol__ Stock Quote Price and Forecast - CNN
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - Minichart
TNXP Looks 393.2% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 - marketscreener.com
Why is Tonix Pharmaceuticals (NASDAQ:TNXP) stock in focus as Wall Street reopens today? - kalkinemedia.com
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer - Yahoo Finance
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
TNXP|Tonix Pharmaceuticals Holding Corp|Price:13.140|Chg%:-0.230 - TradingKey
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - Yahoo Finance
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference - GlobeNewswire
Tonix Pharmaceuticals Holding Corp. (TNXP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock - MarketBeat
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock - Investing.com
Tonix Pharma (NASDAQ: TNXP) CEO adds 2,000 shares in IRA - stocktitan.net
Tonix Pharmaceuticals Holding Corp. (TNXP) Peer Comparison – Compare with Others - Value Research
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Tonix (TNXP) Earnings Report: Profit Per Share Surpasses Its Benchmark in the Latest Reading - careplusvn.com
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada
Tonix Pharmaceuticals director bagger buys $12,600 in stock - Investing.com
Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingFair Value Gap - careplusvn.com
Tonix (TNXP) Results Review: Profit Per Share Surpasses Its Benchmark for the Current Session; Post-Report: The Stock Records a 2.51% Decrease in Latest TradingEarnings Risk Report - careplusvn.com
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript - AOL.com
Tonix Pharma Names CEO Seth Lederman Interim CMO - The Globe and Mail
Tonix (TNXP) Daily Snapshot: Finishes 0.16% Higher at $12.68 in Latest Trading; the $12.05 to $13.31 Range Remains in Focus under the Current SnapshotValue Area High - Vinanet
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline - MarketBeat
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BAGGER RICHARD H | Director |
Aug 20 '26 |
Buy |
12.60 |
1,000 |
12,600 |
1,000 |
| Taylor Carolyn E. | Director |
Jun 12 '26 |
Buy |
10.55 |
1,415 |
14,928 |
1,833 |
| Stillwell Richard Newcomb | Director |
Jun 08 '26 |
Buy |
11.65 |
5,000 |
58,250 |
5,000 |
| LEDERMAN SETH | Chief Executive Officer |
Jun 09 '26 |
Buy |
11.79 |
5,000 |
58,950 |
9,005 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 31 '26 |
Buy |
12.62 |
5,000 |
63,100 |
20,001 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):